Cobalt is the main component of metal prostheses in hip arthroplasty. Studies have shown that metal particles mainly composed of cobalt nanoparticles (CoNPs) can cause systemic and local toxic reactions due to various physical and chemical factors. Therefore, elucidating the underlying mechanisms of metal prosthesis action, coupled with identification of effective detoxification drugs are imperative to minimizing postoperative complications and prolonging the service life of these clinical tools. In this study, we treated Balb/3T3 mouse fibroblast cell line with CoNPs and ferrostatin-1, then measured cell viability via the CCK-8 assay. Next, we determined levels of reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), cobalt and iron contents, as well as glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11) expression in each group. Finally, we employed transmission electron microscopy (TEM) to detect changes in the ultrastructure of each group of cells. Exposure of cells to CoNPs significantly suppressed their viability, and downregulated expression of GSH, GPX4, and SLC7A11 proteins. Conversely, this treatment mediated a significant increase in ROS, MDA, cobalt, and iron levels in the cells. TEM images revealed a marked increase in density of the mitochondrial membrane of cells in the CoNPs group, while the outer membrane was broken. Notably, treatment with ferroptosis inhibitor Ferrostatin-1 alleviated the cytotoxic response caused by CoNPs. These findings suggest that CoNP-induced cytotoxicity may be closely related to ferroptosis, indicating that inhibition of ferroptosis is a potential therapeutic strategy for reducing CoNP toxicity.
Background Currently, tissue damage induced by cobalt nanoparticles (CoNPs) are the most noticeable adverse effect in the patients with metal-on-metal (MOM) hip prostheses. Therefore, effective therapeutic strategy is needed to limit the toxicity of CoNPs. In this study, we aimed to investigate the protective effect of ferroptosis inhibitor on CoNPs-induced cytotoxicity. Methods To evaluate the detoxification effect of ferroptosis inhibitor, MG-63 cells were treated with CoNPs and ferroptosis inhibitor for 24 h. The cell viabilities were measured by CCK-8 assay. The expressions of glutathione peroxidase 4(GPX4) and solute carrier family 7 member 11(SLC7A11) were examined by western blot. Reactive oxygen species (ROS) and the GSH level were measured by the relevant kits. The cell apoptosis was detected by flow cytometry. The serum levels of inflammatory cytokines were measured with Elisa.Results The cytotoxic effects of CoNPs were time- and dose-dependent. In addition, CoNPs elicited a significant (p <0.05) reduction in cell viability and the glutathione (GSH) level with a concomitant increase in ROS generation and inflammatory cytokines such as tumour necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) after 24 hours of exposure. Deferiprone (DFP) provided significant protection for cells after treatment with CoNPs. Western blot analysis demonstrated that CoNPs decreased the expression of GPX4 and SLC7A11, and treatment with DFP inhibited the decrease.Conclusions CoNPs were highly cytotoxic and ferroptosis inhibitor DFP has a detoxification effect on cytotoxicity induced by CoNPs. Ferroptosis plays an important role in the process that CoNPs induced the cytotoxicity. The effectiveness of ferroptosis inhibition on MG-63 cells may initiate the development of novel strategies for reducing the adverse effects associated with metal implants in future.Trial registration: no human participant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.